Metabolic consequences of HIV: Pathogenic insights

Current HIV/AIDS Reports

Volumn 11, Issue 1, 2014, Pages 35-44

  Willig, Amanda L ^a   Overton, E Turner ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

AIDS; Antiretroviral therapy (ART); Cardiovascular disease; Chronic medical condition; Diabetes; Frailty; HIV; HIV pathogenesis; Inflammation; Metabolism; Mitochondria; Pathogenesis

Indexed keywords

HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPOLYSACCHARIDE; NITROGEN DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR 4;

AGING; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; BACTERIAL TRANSLOCATION; BODY COMPOSITION; BONE DENSITY; CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL AGING; CHRONIC DISEASE; CHRONIC INFLAMMATION; COMORBIDITY; DENTAL CARIES; DIABETES MELLITUS; DISEASE ASSOCIATION; FOOD INSECURITY; GERIATRIC PATIENT; GLYCEMIC CONTROL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INNATE IMMUNITY; INSULIN RESISTANCE; INTESTINE FLORA; INTESTINE LYMPHATIC TISSUE; METABOLIC DISORDER; MITOCHONDRIAL TOXICITY; NONHUMAN; NUTRITION; OBESITY; OPPORTUNISTIC INFECTION; OSTEOPOROSIS; PHYSICAL ACTIVITY; POVERTY; PREVALENCE; REVIEW; SMOKING; SUBSTANCE ABUSE; TREATMENT OUTCOME; VIREMIA; VIRUS HEPATITIS; VIRUS PATHOGENESIS; WASTING SYNDROME;

AGE FACTORS; AGING; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; COMORBIDITY; HIV INFECTIONS; HUMANS; METABOLIC DISEASES; RISK FACTORS; UNITED STATES; WASTING SYNDROME;

EID: 84896704396     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-013-0191-7     Document Type: Review

References (108)

1. Palella Jr FJ, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43(1):27-34. (Pubitemid 44306484)
2. • Tate T, Willig AL, Willig JH, Raper JL, Moneyham L, Kempf MC, et al. HIV infection and obesity:where did all the wasting go? Antivir Ther. 2012;17(7):1281-9. This study evaluated 681 patients over a two-year time period. They observed a high rate of overweight/obesity prevalence at ARTinitiation (44%), and a 20% increase in overweight/obesity at two years, with only a modest contribution of ART therapy to weight gain.
3. Vance DE, Mugavero M, Willig J, Raper JL, Aging SMS, With HIV. A Cross-Sectional Study of Comorbidity Prevalence and Clinical Characteristics Across Decades of Life. J Assoc Nurses AIDS Care. 2011;22(1):17-25.
4. Mugavero MJ, Amico KR, Horn T, Thompson MA. The state of engagement in HIV care in the United States: from cascade to continuum to control. Clin Infect Dis Off Publ Infect Dis Soc Am. 2013;57(8):1164-71.
5. Warriner AH, Mugavero MJ. Bone changes and fracture risk in individuals infected with HIV. Curr Rheumatol Rep. 2010;12(3): 163-9.
6. Desquilbet L, Jacobson LP, Fried LP, Phair JP, Jamieson BD, Holloway M, et al. HIV-1 infection is associated with an earlier occurrence of a phenotype related to frailty. J Gerontol A Biol Sci Med Sci. 2007;62(11):1279-86. (Pubitemid 350287617)
7. Terzian AS, Holman S, Nathwani N, Robison E,Weber K, Young M, et al. Factors associated with preclinical disability and frailty among HIV-infected and HIV-uninfected women in the era of cART. J Womens Health (Larchmt). 2009;18(12):1965-74.
8. Schafer I, von Leitner EC, SchonG,Koller D,HansenH,Kolonko T, et al. Multimorbidity patterns in the elderly: a new approach of disease clustering identifies complex interrelations between chronic conditions. PLoS ONE. 2010;5(12):e15941.
9. Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med. 2002;162(20):2269-76. (Pubitemid 35332510)
10. • Kim DJ,Westfall AO, Chamot E,Willig AL, Mugavero MJ, Ritchie C, et al. Multimorbidity patterns in HIV-infected patients: the role of obesity in chronic disease clustering. J Acquir Immune Defic Syndr. 2012;61(5):600-5. This study investigated multimorbidity among over 1800 HIV-infected participants. They found that obesity was associated with increasing odds of multimorbidity, and that three distinct multimorbidity clusters could be identified using exploratory factor analysis: 1) metabolic, 2) behavioral, and 3) substance use.
11. • Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis Off Publ Infect Dis Soc Am. 2011;53(11):1120-6. This case-control study observed that noninfectious comorbidities and polypathology (multimorbidity) occur more often and at a 10-year earlier time frame among HIV-infected patients than in the general population.
12. Guaraldi GZ, S.; Stentarelli C; et al. Aging with HIV versus HIV seroconversion at older age: a diverse population with distinct comorbidity profiles. 4th International Workshop on HIV and Aging; Baltimore, MD2013.
13. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92(7):2506-12. (Pubitemid 47037350)
14. Durand M, Sheehy O, Baril JG, Lelorier J, Tremblay CL. Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Quebec's public health insurance database. J Acquir Immune Defic Syndr. 2011;57(3):245-53.
15. El-Sadr WM, Lundgren J, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355(22):2283-96. (Pubitemid 44837777)
16. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al. Inflammatory and coagulation biomarkers andmortality in patients with HIV infection. PLoS Med. 2008;5(10):e203.
17. Baker JV, Henry WK, Patel P, Bush TJ, Conley LJ, Mack WJ, et al. Progression of carotid intima-media thickness in a contemporary human immunodeficiency virus cohort. Clin Infect Dis Off Publ Infect Dis Soc Am. 2011;53(8):826-35.
18. • Yarasheski KE, Laciny E, Overton ET, Reeds DN, Harrod M, Baldwin S, et al. 18FDG PET-CT imaging detects arterial inflammation and early atherosclerosis in HIV-infected adults with cardiovascular disease risk factors. J Inflamm (Lond). 2012;9(1):26. This study confirmed carotid artery 18FDG PET-CT imaging as an effective technique to observe differences between HIV-infected adults versus controls in vascular inflammation and early atherosclerosis.
19. • Zanni MV, Abbara S, Lo J, Wai B, Hark D, Marmarelis E, et al. Increased coronary atherosclerotic plaque vulnerability by coronary computed tomography angiography in HIV-infected men. AIDS. 2013;27(8):1263-72. This study observed a significantly greater presence of vulnerable plaques - low attenuation plaque and high-risk 3-feature plaque - in HIV-infected patients that may partly explain the high rates of myocardial infarction and sudden cardiac death in this population.
20. Friis-Moller N,Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio Monforte A, et al. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17(8):1179-93. (Pubitemid 36667761)
21. Torriani FJ, Komarow L, Parker RA, Cotter BR, Currier JS, Dube MP, et al. Endothelial function in human immunodeficiency virusinfected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152 s. J Am Coll Cardiol. 2008;52(7):569-76.
22. Kitagawa T, Yamamoto H, Horiguchi J, Ohhashi N, Tadehara F, Shokawa T, et al. Characterization of noncalcified coronary plaques and identification of culprit lesions in patients with acute coronary syndrome by 64-slice computed tomography. JACC Cardiovasc Imaging. 2009;2(2):153-60.
23. Rominger A, Saam T,Wolpers S, Cyran CC, SchmidtM, Foerster S, et al. 18 F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. J Nucl Med. 2009;50(10):1611-20.
24. Hsue PY, Scherzer R, Hunt PW, Schnell A, Bolger AF, Kalapus SC et al. Carotid Intima-Media Thickness Progression in HIV-Infected Adults Occurs Preferentially at the Carotid Bifurcation and Is Predicted by Inflammation. Journal of the American Heart Association. 2012;1(2):1-12.
25. Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, Riddler SA, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 2005;165(10):1179-84. (Pubitemid 40720744)
26. Adeyemi OM, Livak B, Orsi J, Glesby MJ, Villacres MC, Weber KM, et al. Vitamin D and insulin resistance in non-diabetic women's interagency HIV study participants. AIDS Patient Care STDs. 2013;27(6):320-5.
27. Grunfeld C, Rimland D, Gibert CL, Powderly WG, Sidney S, ShlipakMG, et al. Association of upper trunk and visceral adipose tissue volume with insulin resistance in control and HIV-infected subjects in the FRAM study. J Acquir Immune Defic Syndr. 2007;46(3):283-90. (Pubitemid 350287354)
28. De Wit S, Sabin CA, Weber R, Worm SW, Reiss P, Cazanave C, et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care. 2008;31(6):1224-9.
29. Kino T, Gragerov A, Slobodskaya O, Tsopanomichalou M, Chrousos GP, Pavlakis GN. Human immunodeficiency virus type 1 (HIV-1) accessory protein Vpr induces transcription of the HIV-1 and glucocorticoid-responsive promoters by binding directly to p300/CBP coactivators. J Virol. 2002;76(19):9724-34. (Pubitemid 35006513)
30. Shrivastav S, Kino T, Cunningham T, Ichijo T, Schubert U, Heinklein P, et al. Human immunodeficiency virus (HIV)-1 viral protein R suppresses transcriptional activity of peroxisome proliferator-activated receptor gamma and inhibits adipocyte differentiation: implications for HIV-associated lipodystrophy. Mol Endocrinol. 2008;22(2):234-47. (Pubitemid 351185928)
31. Meininger G, Hadigan C, Laposata M, Brown J, Rabe J, Louca J, et al. Elevated concentrations of free fatty acids are associated with increased insulin response to standard glucose challenge in human immunodeficiency virus-infected subjects with fat redistribution. Metab Clin Exp. 2002;51(2):260-6. (Pubitemid 34168243)
32. Overton ETT, P, Ryan, R, Coate B, Perniciaro, A, Dayaram, YK, De La Rosa, G, Baugh, B. Once daily Darunavir/Ritonavir (DRV/r) versus Atazanavir/Ritonavir (ATV/r) on insulin sensitivity in HIV-infected persons over 48 weeks. Poster Presentation 53rd ICAAC. 2013;September 10 - 13,2013. Denver, CO:Abstract #2147.
33. Reeds DC, WT, Patterson, BW, Overton, T, Yarasheski, KE, Klein, S. Metabolic benefits of weight loss are blunted in obese, HIV-infected women. Obesity. 2011;19 (S1):S112.
34. Han JH, Crane HM, Bellamy SL, Frank I, Cardillo S, Bisson GP, et al. HIV infection and glycemic response to newly initiated diabetic medical therapy. AIDS. 2012;26(16):2087-95.
35. • Brown TT, Tassiopoulos K, Bosch RJ, Shikuma C, McComsey GA. Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy. Diabetes Care. 2010;33(10):2244-9. This retrospective study identified a relationship between diabetes risk and sTNFR1, sTNFR2 and hs-CRP among HIV-infected patients with and without a diabetes diagnosis.
36. Hansen AB, Gerstoft J, Kronborg G, Larsen CS, Pedersen C, Pedersen G, et al. Incidence of low and high-energy fractures in persons with and without HIV infection: a Danish population-based cohort study. AIDS. 2012;26(3):285-93.
37. Womack JA, Goulet JL, Gibert C, Brandt CA, Skanderson M, Gulanski B, et al. Physiologic frailty and fragility fracture in HIV infected male veterans. Clin Infect Dis Off Publ Infect Dis Soc Am. 2013;56(10):1498-504.
38. Yin MT, Kendall MA, Wu X, Tassiopoulos K, Hochberg M, Huang JS, et al. Fractures after antiretroviral initiation. AIDS. 2012;26(17):2175-84.
39. • YinMT, Lund E, Shah J, Zhang CA, Foca M, Neu N et al. Lower peak bone mass and abnormal trabecular and cortical microarchitecture in young men infected with HIV early in life. Aids. 2013 Sep 25. [Epub ahead of print].
40. Tanchaweng SP, T.; Saksawad, R.; Brukesawan, C.; Maleesantharn, A.; Chokephaibulkit, K. Longitudinal study of bone mineral density and vitamin D levels among perinatally HIV-infected Thai adolescents on long-term antiretroviral therapy. 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 2013;June 30-July 3, 2013. Kuala Lumpur:Abstract MOPDB0103.
41. Grant PM, Kitch D, McComsey GA, Dube MP, Haubrich R, Huang J, et al. Low Baseline CD4+ Count Is Associated With Greater Bone Mineral Density Loss After Antiretroviral Therapy Initiation. Clin Infect Dis Off Publ Infect Dis Soc Am. 2013;57(10):1483-8.
42. Titanji KV, A.; Sheth, A.; Lennox, J.;Weitzmann, N.; Ofotokun, I. B cell dysregulation promotes HIV-induced bone loss. Conference on Retroviruses and Opportunistic Infections. 2013;March 3-6, 2013. Atlanta, GA:Abstract 821.
43. • Hernandez-Vallejo SJ, Beaupere C, Larghero J, Capeau J, Lagathu C. HIV protease inhibitors induce senescence and alter osteoblastic potential of human bone marrow mesenchymal stem cells: beneficial effect of pravastatin. Aging Cell. 2013. doi: 10.1111/acel.12119.
44. Althoff KN, Jacobson LP, Cranston RD, Detels R, Phair JP, Li X et al. Age, Comorbidities, and AIDS Predict a Frailty Phenotype in Men Who Have Sex With Men. The journals of gerontology Series A, Biological sciences and medical sciences. 2013. Oct 14. [Epub ahead of print].
45. Onen NF, Agbebi A, Shacham E, Stamm KE, Onen AR, Overton ET. Frailty among HIV-infected persons in an urban outpatient care setting. J Infect. 2009;59(5):346-52.
46. McMillan GJ, Hubbard RE. Frailty in older inpatients: what physicians need to know. QJM Mon J Assoc Phys. 2012;105(11):1059-65.
47. Michaud M, Balardy L, Moulis G, Gaudin C, Peyrot C, Vellas B, et al. Proinflammatory Cytokines, Aging, and Age-Related Diseases. J Am Med Dir Assoc. 2013;14(12):877-82.
48. • Erlandson KM, Allshouse AA, Jankowski CM, Lee EJ, Rufner KM, Palmer BE, et al. Association of functional impairment with inflammation and immune activation in HIV type 1-infected adults receiving effective antiretroviral therapy. J Infect Dis. 2013;208(2):249-59. This study found that functional impairment following ART initiation is associated with higher CD8+ t-cell activation and higher IL-6 levels.
49. • Reekie J, Gatell JM, Yust I, Bakowska E, Rakhmanova A, Losso M, et al. Fatal and nonfatal AIDS and non-AIDS events in HIV-1-positive individuals with high CD4 cell counts according to viral load strata. AIDS. 2011;25(18):2259-68. This study showed that, among patients with CD4+ t-cell counts > 350 cells/mul, uncontrolled viral replication was associated with increased incidence of AIDS.
50. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA J Am Med Assoc. 2012;308(4):387-402.
51. Chung HY, CesariM, Anton S,Marzetti E, Giovannini S, Seo AY, et al. Molecular inflammation: underpinnings of aging and age-related diseases. Ageing Res Rev. 2009;8(1):18-30.
52. Howcroft TK, Campisi J, Louis GB, Smith MT, Wise B, Wyss-Coray T, et al. The role of inflammation in age-related disease. Aging (Albany NY). 2013;5(1):84-93.
53. Tchkonia T, Zhu Y, van Deursen J, Campisi J, Kirkland JL. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J Clin Investig. 2013;123(3):966-72.
54. Khan N, Shariff N, CobboldM, Bruton R, Ainsworth JA, Sinclair AJ, et al. Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals. J Immunol. 2002;169(4):1984-92. (Pubitemid 34857662)
55. Pathai S, Bajillan H, Landay AL, High KP. Is HIV a Model of Accelerated or Accentuated Aging? The journals of gerontology Series A, Biological sciences and medical sciences. 2013.
56. Scholer A, Hugues S, Boissonnas A, Fetler L, Amigorena S. Intercellular adhesion molecule-1-dependent stable interactions between T cells and dendritic cells determine CD8+ T cell memory. Immunity. 2008;28(2):258-70. (Pubitemid 351222655)
57. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12(12): 1365-71. (Pubitemid 44924494)
58. Gordon SN, Cervasi B, Odorizzi P, Silverman R, Aberra F, Ginsberg G, et al. Disruption of intestinal CD4+ T cell homeostasis is a key marker of systemic CD4+ T cell activation in HIV-infected individuals. J Immunol. 2010;185(9):5169-79.
59. Li Q, Estes JD, Duan L, Jessurun J, Pambuccian S, Forster C, et al. Simian immunodeficiency virus-induced intestinal cell apoptosis is the underlying mechanism of the regenerative enteropathy of early infection. J Infect Dis. 2008;197(3):420-9. (Pubitemid 351263424)
60. Lederman MM, Calabrese L, Funderburg NT, Clagett B, Medvik K, Bonilla H, et al. Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J Infect Dis. 2011;204(8):1217-26.
61. Robbins GK, Spritzler JG, Chan ES, Asmuth DM, Gandhi RT, Rodriguez BA, et al. Incomplete reconstitution of Tcell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. Clin Infect Dis Off Publ Infect Dis Soc Am. 2009;48(3):350-61.
62. Ellis CL, Ma ZM, Mann SK, Li CS, Wu J, Knight TH, et al. Molecular characterization of stool microbiota in HIV-infected subjects by panbacterial and order-level 16S ribosomal DNA (rDNA) quantification and correlations with immune activation. J Acquir Immune Defic Syndr. 2011;57(5):363-70.
63. Gori A, Tincati C, Rizzardini G, Torti C, Quirino T, Haarman M, et al. Early impairment of gut function and gut flora supporting a role for alteration of gastrointestinal mucosa in human immunodeficiency virus pathogenesis. J Clin Microbiol. 2008;46(2): 757-8. (Pubitemid 351231331)
64. Vujkovic-Cvijin I, DunhamRM, Iwai S,MaherMC, Albright RG, Broadhurst MJ, et al. Dysbiosis of the gut microbiota is associated with hiv disease progression and tryptophan catabolism. Sci Transl Med. 2013;5(193):193ra91.
65. van der Velde AE. Reverse cholesterol transport: from classical view to new insights. World J Gastroenterol WJG. 2010;16(47): 5908-15.
66. Huang CY, Chiang SF, Lin TY, Chiou SH, Chow KC. HIV-1 Vpr triggers mitochondrial destruction by impairing Mfn2-mediated ER-mitochondria interaction. PLoS ONE. 2012;7(3):e33657.
67. Pearce EL, Poffenberger MC, Chang CH, Jones RG. Fueling immunity: insights into metabolism and lymphocyte function. Science. 2013;342(6155): 1242454.
68. LeowMK, Addy CL,Mantzoros CS. Clinical review 159: Human immunodeficiency virus/highly active antiretroviral therapyassociated metabolic syndrome: clinical presentation, pathophysiology, and therapeutic strategies. J Clin Endocrinol Metab. 2003;88(5):1961-76. (Pubitemid 36549862)
69. Joy T, Keogh HM, Hadigan C, Dolan SE, Fitch K, Liebau J, et al. Relation of body composition to body mass index in HIV-infected patients with metabolic abnormalities. J Acquir Immune Defic Syndr. 2008;47(2):174-84. (Pubitemid 351172184)
70. Grunfeld C, Saag M, Cofrancesco Jr J, Lewis CE, Kronmal R, Heymsfield S, et al. Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy. AIDS. 2010;24(11): 1717-26.
71. Koethe JR, Hulgan T, Niswender K. Adipose Tissue and Immune Function: A Review of Evidence Relevant to HIV Infection. J Infect Dis. 2013;208(8):1194- 201.
72. Grunfeld C, Pang M, Shimizu L, Shigenaga JK, Jensen P, Feingold KR. Resting energy expenditure, caloric intake, and short-term weight change in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Am J Clin Nutr. 1992;55(2):455-60.
73. Melchior JC, Raguin G, Boulier A, Bouvet E, Rigaud D, Matheron S, et al. Resting energy expenditure in human immunodeficiency virus-infected patients: comparison between patients with and without secondary infections. Am J Clin Nutr. 1993;57(5):614-9. (Pubitemid 23132792)
74. Mittelsteadt AL, Hileman CO, Harris SR, Payne KM, Gripshover BM,McComsey GA. Effects of HIV and antiretroviral therapy on resting energy expenditure in adult HIV-infected women-a matched, prospective, cross-sectional study. J Acad Nutr Diet. 2013;113(8):1037-43.
75. Kosmiski LA, Sage-El A, Kealey EH, Bessesen DH. Brown fat activity is not apparent in subjects with HIV lipodystrophy and increased resting energy expenditure. Obesity. 2011;19(10): 2096-8.
76. Tesoriero JM, Gieryic SM, Carrascal A, Lavigne HE. Smoking among HIV positive New Yorkers: prevalence, frequency, and opportunities for cessation. AIDS Behav. 2010;14(4):824-35.
77. (CDC) CfDCaP. Vital signs: current cigarette smoking among sdults aged > 18 years with mental illnes - United States, 2990-2011. Morb Mortal Wkly Rep. 2013;62(5):81-7.
78. Feldman JG, Minkoff H, Schneider MF, Gange SJ, Cohen M, Watts DH, et al. Association of cigarette smoking with HIV prognosis among women in the HAART era: a report from the women's interagency HIV study. Am J Publ Health. 2006;96(6): 1060-5. (Pubitemid 43825275)
79. Grubb JR, Overton ET, Presti R, Onen NF. Reply to Ganesan et al. J Infect Dis. 2012;205(3):518-9.
80. Kalichman SC, Cherry C, Amaral C, White D, Kalichman MO, Pope H, et al. Health and treatment implications of food insufficiency among people living with HIV/AIDS, Atlanta, Georgia. J Urban Health. 2010;87(4):631-41.
81. Weiser SD, Bangsberg DR, Kegeles S, Ragland K, Kushel MB, Frongillo EA. Food insecurity among homeless and marginally housed individuals living with HIV/AIDS in San Francisco. AIDS Behav. 2009;13(5):841-8.
82. Anema A, Vogenthaler N, Frongillo EA, Kadiyala S, Weiser SD. Food insecurity and HIV/AIDS: current knowledge, gaps, and research priorities. Curr HIV/AIDS Rep. 2009;6(4):224-31.
83. Weiser SD, Fernandes KA, Brandson EK, Lima VD, Anema A, Bangsberg DR, et al. The association between food insecurity and mortality among HIV-infected individuals on HAART. J Acquir Immune Defic Syndr. 2009;52(3):342-9.
84. Stradling C, Chen YF, Russell T, ConnockM, Thomas GN, Taheri S. The effects of dietary intervention on HIV dyslipidaemia: a systematic review and meta-analysis. PLoS ONE. 2012;7(6): e38121.
85. Viskovic K, Rutherford GW, Sudario G, Stemberger L, Brnic Z, Begovac J. Ultrasound measurements of carotid intima-media thickness and plaque in HIV-infected patients on the Mediterranean diet. Croat Med J. 2013;54(4):330-8.
86. Crum-Cianflone N, RoedigerMP, Eberly L, HeaddM,Marconi V, Ganesan A, et al. Increasing rates of obesity among HIV-infected persons during the HIV epidemic. PLoS One. 2010;5(4):e10106.
87. Bogers RP, Bemelmans WJ, Hoogenveen RT, Boshuizen HC, Woodward M, Knekt P, et al. Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: a meta-analysis of 21 cohort studies including more than 300 000 persons. Arch Intern Med. 2007;167(16):1720-8. (Pubitemid 47403058)
88. Greenfield JR, Samaras K, Jenkins AB, Kelly PJ, Spector TD, Gallimore JR, et al. Obesity is an important determinant of baseline serumC-reactive protein concentration inmonozygotic twins, independent of genetic influences. Circulation. 2004;109(24): 3022-8. (Pubitemid 38808325)
89. Crum-Cianflone NF, Roediger M, Eberly LE, Ganesan A, Weintrob A, Johnson E, et al. Impact of weight on immune cell counts among HIV-infected persons. Clin Vaccine Immunol CVI. 2011;18(6):940-6.
90. Koethe JR, Jenkins CA, Shepherd BE, Stinnette SE, Sterling TR. An optimal body mass index range associated with improved immune reconstitution among HIV-infected adults initiating antiretroviral therapy. Clin Infect Dis Off Publ Infect Dis Soc Am. 2011;53(9):952-60.
91. Womack J, Tien PC, Feldman J, Shin JH, Fennie K, Anastos K, et al. Obesity and immune cell counts in women.Metab Clin Exp. 2007;56(7):998-1004. (Pubitemid 46890984)
92. Blashill AJ, Mayer KH, Crane HM, Grasso C, Safren SA. Body Mass Index, Immune Status, and Virological Control in HIV-Infected Men Who Have Sex with Men. J Int Assoc Providers AIDS Care. 2013;12(5):319-24.
93. Engelson ES, Agin D, Kenya S,Werber-Zion G, Luty B, Albu JB, et al. Body composition and metabolic effects of a diet and exercise weight loss regimen on obese, HIV-infected women. Metab Clin Exp. 2006;55(10):1327-36. (Pubitemid 44354946)
94. Phelan JA, Mulligan R, Nelson E, Brunelle J, Alves ME, Navazesh M, et al. Dental caries in HIV-seropositive women. J Dent Res. 2004;83(11):869-73. (Pubitemid 41756901)
95. Davoodi P, Hamian M, Nourbaksh R, Ahmadi MF. Oral Manifestations Related To CD4 Lymphocyte Count in HIV-Positive Patients. J Dent Res Dent Clin Dent Prospects. 2010;4(4):115-9.
96. NittayanantaW, Talungchit S, Jaruratanasirikul S, Silpapojakul K, Chayakul P, Nilmanat A, et al. Effects of long-termuse ofHAART on oral health status of HIV-infected subjects. J Oral Pathol Med. 2010;39(5):397-406.
97. McLachlan JL, Sloan AJ, Smith AJ, Landini G, Cooper PR. S100 and cytokine expression in caries. Infect Immun. 2004;72(7): 4102-8. (Pubitemid 38821925)
98. Graham CS, Baden LR, Yu E,Mrus JM, Carnie J, Heeren T, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Inf Dis Off Publ Infect Dis Soc Am. 2001;33(4):562-9. (Pubitemid 32709592)
99. BonaciniM. Alcohol use among patients with HIV infection. Ann Hepatol. 2011;10(4):502-7.
100. Chaudhry AA, SulkowskiMS, Chander G,Moore RD. Hazardous drinking is associated with an elevated aspartate aminotransferase to platelet ratio index in an urban HIV-infected clinical cohort. HIV Med. 2009;10(3):133-42.
101. Balagopal A, Philp FH,Astemborski J, Block TM, Mehta A, Long R, et al. Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology. 2008;135(1):226-33. (Pubitemid 351899010)
102. Joshi D, O'Grady J, Dieterich D, Gazzard B, Agarwal K. Increasing burden of liver disease in patients with HIV infection. Lancet. 2011;377(9772):1198- 209.
103. LinW,Weinberg EM, Tai AW, Peng LF, BrockmanMA, KimKA, et al. HIV increases HCV replication in a TGF-beta1-dependent manner. Gastroenterology. 2008;134(3):803-11. (Pubitemid 351312737)
104. Morse CG, Voss JG, Rakocevic G, McLaughlin M, Vinton CL, Huber C, et al. HIV infection and antiretroviral therapy have divergent effects on mitochondria in adipose tissue. J Infect Dis. 2012;205(12):1778-87.
105. Bhargava A, Raghuram GV, Pathak N, Varshney S, Jatawa SK, Jain D, et al. Occult hepatitis C virus elicits mitochondrial oxidative stress in lymphocytes and triggers PI3-kinase-mediated DNA damage response. Free Radic Biol Med. 2011;51(9):1806-14.
106. • Chapplain JM, Tattevin P, Guyader D, Begue JM, Beillot J, Turlin B, et al. Mitochondrial abnormalities in patients with HIV-HCV co-infection as compared to patients with HCV mono-infection. HIV Clin Trials. 2011;12(1):54-60. This study showed that HCV infection is independently associated with liver mitochondrial dysfunction in HIV-infected patients.
107. Wallace DC. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev Genet. 2005;39:359-407. (Pubitemid 43011120)
108. • Hatano H, Yukl SA, Ferre AL, Graf EH, Somsouk M, Sinclair E, et al. Prospective Antiretroviral Treatment of Asymptomatic, HIV-1 Infected Controllers. PLoS Pathog. 2013;9(10):e1003691. This study showed that HIV replication continues in elite controllers with low levels of plasma HIV RNA, and that this subset of patients may benefit from initiation of ART to control chronic, systemic inflammation.